Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 31, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transaction details within a retirement savings plan.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- January 19, 2006: Holdings decreased from 18,409,914 to 18,383,870 ADRs at an average price of $51.60.
- January 26, 2006: Holdings decreased from 18,383,870 to 18,075,774 ADRs at an average price of $50.75.
These movements were notified by the Plan Administrators on January 23 and January 27, 2006, respectively.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that the Plan is a discretionary fund for employees and former employees, and that Directors Dr. J P Garnier and Dr. T Yamada are potentially interested in the shares held in the fund in the same manner as other employees.
Investor Verification Points
- Verify the total reduction in ADR holdings within the US Retirement Savings Plan during January 2006.
- Confirm the average transaction prices of $51.60 and $50.75 against market data for the respective dates.
- Note that the reported transactions are attributed to fund movements rather than direct discretionary trading by the named directors.